Prime Medicine (PRME) Jefferies London Healthcare Conference 2024 summary

Technology overview and differentiation

• Prime Editing enables versatile genome edits, including deletions, insertions, point mutations, and large segment excisions, surpassing the capabilities of CRISPR-Cas9 and base editing technologies.

• Proprietary delivery platforms include a universal LNP for liver programs and electroporation for ex vivo applications, with AAV used in some paused programs.

• PASSIGE technology allows for precise, large gene insertions, expanding therapeutic potential.

Pipeline reprioritization and strategic focus

• Pipeline narrowed from over 18 programs to focus on those with strong commercial opportunity, unmet need, and clinical tractability.

• Wilson's disease and chronic granulomatous disease (CGD) prioritized due to market size, competitive landscape, and delivery feasibility.

• Programs in ocular and GSD1b deprioritized due to clinical or market limitations.

• Cost of capital and value creation drive program selection, with potential to revisit paused areas in the future.

Strategic partnerships and business development

• Secured a major partnership with BMS, including $110M upfront, $185M in preclinical milestones, and $1.2B in development milestones.

• Collaboration focuses on non-viral, high-efficiency CAR T cell therapies using Prime Editing.

• BMS deal has increased interest from other potential partners, with ongoing discussions for additional collaborations.

• Business development seen as a key funding and patient access mechanism moving forward.